key: cord-0850259-f0a16f17
authors: Mina, Fahmida Begum; Billah, Mutasim; Rahman, Siddikur; Das, Sabuj; Karmakar, Sumon; Acharjee, Uzzal Kumar; Hasan, Faruk
title: Convalescent Plasma: Alternative or Promising Therapy?
date: 2021-01-18
journal: J Glob Antimicrob Resist
DOI: 10.1016/j.jgar.2021.01.001
sha: 07ebde5c36d003f825684025fa7229d13a8c9c42
doc_id: 850259
cord_uid: f0a16f17

• COVID-19 is an emerging viral threat for public health and Convalescent plasma (CP) is a specific therapy for COVID-19. • This therapy is safe and effective in COVID-19 patients. • The SARS-CoV-2 neutralizing antibody in the convalescent plasma helps to control COVID-19 infection and modulates inflammatory response. • Plasma components may enhance the antiviral and anti-inflammatory properties of convalescent plasma. • CP therapy seems healthy, clinically successful and decreases mortality in the COVID-19 patients.

medium term by quickly strengthening a person's passive immune system against a virus, and health professionals can transfer the antibody-rich blood plasma of freshly healed patients to those critical ones.

The use of convalescent plasma dates back to the 1900s but has more recent precedents, which indicate its efficacy as a relatively effective stopgap measure against evolving viral infections. From H1N1 influenza to Ebola to the foremost predecessor of COVID-19, SARS, medical practitioners have constantly switched to this specific type of passive immune therapy and documented encouraging decreases in mortality and viral loads in many cases. Upon the emergence of the COVID-19 pandemic, some researchers proposed convalescent plasma treatment as a possible therapeutic as the use of plasma from patients after certain days or few weeks of recovering from COVID-19 has the potential advantage of supplying appropriate disease neutralizing antibodies, before structured therapies can be developed [1] .

When a patient makes a complete recovery from COVID-19, the IgG antibodies will maintain a recollection of the disease for at least couple of months, ready to combat the infection.

Although immunoglobulin M (IgM) antibodies, the largest and first to be formed, vanish shortly after their role as the initial line of defense has been performed, immunoglobulin G (IgG) antibodies in all body fluids persist plentiful, ready to jump into action if the virus ever resumes. Whereas convalescent sera, which is manufactured and distributed through a network of hospitals and securitizations, the preparation of hyperimmune globulins requires proper manufacturing base, particularly on a commercial scale.

Hyperimmune globulins have already been produced and even prepared for SARS, for diseases such as cytomegalovirus, H1N1 and hepatitis as numerous plasma manufacturers are attempting to develop the hyperimmune sera specific to SARS-CoV2, e.g. TAK-888 by Takeda, and anti-COVID19 IgG by Kamada.

The goal is to identify and measure strongly neutralizing antibodies, those best suited to battling the virus, (Table 1 : Plasma-Based Therapies). although the details are minimal, convalescent Plasma therapy seems healthy, clinically successful and decreases mortality in the COVID-19 patients [4] . Established plasma transfusion threats include inadvertent contact with any contagious pathogen, such as with any blood component, and patients with other immunodeficiencies or lung-related comorbidities, such as transfusion-related circulatory dysfunction (TACO) and transfusion-related acute lung injury (TRALI) among the most vulnerable to COVID-19, may not qualify for convalescent plasma treatment [5] . For so many lives on the table, with so few medical options, these risks may be worthwhile taking in the fight against SARS-CoV-2 pandemic.

Funding: None of the authors has any financial supports to complete the content of the manuscript.

Ethical Approval: Not required.

Competing Interest: The all authors declare no conflicts of interest.

J o u r n a l P r e -p r o o f

Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study

Covid-19: FDA approves use of convalescent plasma to treat critically ill patients

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Treatment of 5 critically ill patients with COVID-19 with convalescent plasma

Convalescent plasma to treat COVID-19: possibilities and challenges

We express our deepest gratitude and thanks to almighty, our parents, families, teachers, and all those who helped and supported us along the way.J o u r n a l P r e -p r o o f